Experts have developed a breakthrough small-molecule drug, a ‘protein degrader’. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for all patients with cancers caused by KRAS mutations.
Geiger Mueller News Service